{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:36:44Z","timestamp":1787960204047,"version":"build-2784847793"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ahj.2017.11.013","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T04:12:49Z","timestamp":1512533569000},"page":"103-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease"],"prefix":"10.1016","volume":"197","author":[{"given":"Doyeon","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Myung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Min","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeong-Ki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangsoo","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Gilard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullio","family":"Palmerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"37","key":"10.1016\/j.ahj.2017.11.013_bb0005","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.ahj.2017.11.013_bb0010","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMoa035071","article-title":"Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery","volume":"349","author":"Moses","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ahj.2017.11.013_bb0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa032441","article-title":"A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease","volume":"350","author":"Stone","year":"2004","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ahj.2017.11.013_bb0020","first-page":"e574","article-title":"2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ahj.2017.11.013_bb0025","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jacc.2015.05.053","article-title":"Duration of dual antiplatelet therapy after coronary stenting: A review of the evidence","volume":"66","author":"Montalescot","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.ahj.2017.11.013_bb0030","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","author":"Park","year":"2010","journal-title":"N Engl J Med"},{"issue":"9954","key":"10.1016\/j.ahj.2017.11.013_bb0035","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ahj.2017.11.013_bb0040","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ahj.2017.11.013_bb0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2174\/1573403X10666140214122234","article-title":"Coronary artery disease in patients with chronic kidney disease: a clinical update","volume":"9","author":"Cai","year":"2013","journal-title":"Curr Cardiol Rev"},{"issue":"10","key":"10.1016\/j.ahj.2017.11.013_bb0050","first-page":"1170","article-title":"Association between drug-eluting stent type and clinical outcomes in patients with chronic kidney disease undergoing percutaneous coronary intervention","volume":"30","author":"Chan","year":"2014","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2017.11.013_bb0055","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijcard.2014.04.269","article-title":"Trend in the use of drug eluting stents in the United States: insight from over 8.1 million coronary interventions","volume":"175","author":"Bangalore","year":"2014","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2017.11.013_bb0060","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ahj.2017.11.013_bb0065","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.ahj.2017.11.013_bb0070","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.ahj.2017.11.013_bb0075","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ahj.2017.11.013_bb0080","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.ahj.2017.11.013_bb0085","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jacc.2014.12.046","article-title":"Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis","volume":"65","author":"Palmerini","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.ahj.2017.11.013_bb0090","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ahj.2017.11.013_bb0095","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"17","key":"10.1016\/j.ahj.2017.11.013_bb0100","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"issue":"9888","key":"10.1016\/j.ahj.2017.11.013_bb0105","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ahj.2017.11.013_bb0110","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1161\/CIRCULATIONAHA.111.084996","article-title":"Antithrombotic therapy in patients with chronic kidney disease","volume":"125","author":"Capodanno","year":"2012","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ahj.2017.11.013_bb0115","doi-asserted-by":"crossref","first-page":"e002230","DOI":"10.1161\/CIRCINTERVENTIONS.114.002230","article-title":"Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial","volume":"8","author":"Iqbal","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.ahj.2017.11.013_bb0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jcin.2008.06.012","article-title":"In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry","volume":"2","author":"Latif","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"10.1016\/j.ahj.2017.11.013_bb0125","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/0003319711398864","article-title":"The relationship between chronic kidney disease and SYNTAX score","volume":"62","author":"Coskun","year":"2011","journal-title":"Angiology"},{"issue":"2","key":"10.1016\/j.ahj.2017.11.013_bb0130","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijcard.2010.01.001","article-title":"Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents","volume":"149","author":"Choi","year":"2011","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.ahj.2017.11.013_bb0135","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehq480","article-title":"Comparison of haemodialysis patients and non-haemodialysis patients with respect to clinical characteristics and 3-year clinical outcomes after sirolimus-eluting stent implantation: insights from the Japan multi-centre post-marketing surveillance registry","volume":"32","author":"Otsuka","year":"2011","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.ahj.2017.11.013_bb0140","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/heartjnl-2014-307168","article-title":"Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease","volume":"101","author":"Siddiqi","year":"2015","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.ahj.2017.11.013_bb0145","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","article-title":"The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"155","author":"Best","year":"2008","journal-title":"Am Heart J"},{"issue":"15","key":"10.1016\/j.ahj.2017.11.013_bb0150","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jacc.2011.06.049","article-title":"Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials","volume":"58","author":"Baber","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"9824","key":"10.1016\/j.ahj.2017.11.013_bb0155","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(12)60324-9","article-title":"Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis","volume":"379","author":"Palmerini","year":"2012","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ahj.2017.11.013_bb0160","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.jcin.2016.06.051","article-title":"Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era: Pooled Analysis of the Korean Multicenter Drug-Eluting Stent Registry","volume":"9","author":"Lee","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"10.1016\/j.ahj.2017.11.013_bb0165","doi-asserted-by":"crossref","first-page":"e001683","DOI":"10.1161\/CIRCINTERVENTIONS.115.001683","article-title":"Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry","volume":"8","author":"Baber","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"5","key":"10.1016\/j.ahj.2017.11.013_bb0170","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jtcvs.2016.07.044","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"152","author":"Levine","year":"2016","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317303800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317303800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:59:58Z","timestamp":1757570398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870317303800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":34,"alternative-id":["S0002870317303800"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2017.11.013","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2017.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}